Cello World Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 15, 2025, 10:41 pm

Competitors of Cello World Ltd

All Competitor Stocks of Cello World Ltd

Quarterly Result

Last Updated: October 17, 2025, 11:20 am

Below is a detailed analysis of the quarterly data for Cello World Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 529.00 Cr.. The value appears to be declining and may need further review. It has decreased from 589.00 Cr. (Mar 2025) to 529.00 Cr., marking a decrease of 60.00 Cr..
• For Expenses, as of Jun 2025, the value is 420.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 454.00 Cr. (Mar 2025) to 420.00 Cr., marking a decrease of 34.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 109.00 Cr.. The value appears to be declining and may need further review. It has decreased from 135.00 Cr. (Mar 2025) to 109.00 Cr., marking a decrease of 26.00 Cr..
• For OPM %, as of Jun 2025, the value is 21.00%. The value appears to be declining and may need further review. It has decreased from 23.00% (Mar 2025) to 21.00%, marking a decrease of 2.00%.
• For Other Income, as of Jun 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Mar 2025) to 17.00 Cr., marking an increase of 4.00 Cr..
• For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
• For Depreciation, as of Jun 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.00 Cr. (Mar 2025) to 19.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 108.00 Cr.. The value appears to be declining and may need further review. It has decreased from 130.00 Cr. (Mar 2025) to 108.00 Cr., marking a decrease of 22.00 Cr..
• For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to 25.00%, marking a decrease of 1.00%.
• For Net Profit, as of Jun 2025, the value is 81.00 Cr.. The value appears to be declining and may need further review. It has decreased from 96.00 Cr. (Mar 2025) to 81.00 Cr., marking a decrease of 15.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 3.31. The value appears to be declining and may need further review. It has decreased from 3.99 (Mar 2025) to 3.31, marking a decrease of 0.68.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 3:41 am

Growth

Last Updated: September 5, 2025, 2:51 pm

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Cello World Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 15.50. This value is within the healthy range. It has decreased from 15.60 (Mar 24) to 15.50, marking a decrease of 0.10.
• For Diluted EPS (Rs.), as of Mar 25, the value is 15.50. This value is within the healthy range. It has decreased from 15.60 (Mar 24) to 15.50, marking a decrease of 0.10.
• For Cash EPS (Rs.), as of Mar 25, the value is 19.33. This value is within the healthy range. It has decreased from 19.48 (Mar 24) to 19.33, marking a decrease of 0.15.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 98.12. It has increased from 54.15 (Mar 24) to 98.12, marking an increase of 43.97.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 98.12. It has increased from 54.15 (Mar 24) to 98.12, marking an increase of 43.97.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 96.72. It has increased from 94.25 (Mar 24) to 96.72, marking an increase of 2.47.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 25.13. This value is within the healthy range. It has decreased from 25.20 (Mar 24) to 25.13, marking a decrease of 0.07.
• For PBIT / Share (Rs.), as of Mar 25, the value is 22.32. This value is within the healthy range. It has decreased from 22.52 (Mar 24) to 22.32, marking a decrease of 0.20.
• For PBT / Share (Rs.), as of Mar 25, the value is 22.26. This value is within the healthy range. It has decreased from 22.40 (Mar 24) to 22.26, marking a decrease of 0.14.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 16.52. This value is within the healthy range. It has decreased from 16.81 (Mar 24) to 16.52, marking a decrease of 0.29.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 15.34. This value is within the healthy range. It has decreased from 15.60 (Mar 24) to 15.34, marking a decrease of 0.26.
• For PBDIT Margin (%), as of Mar 25, the value is 25.98. This value is within the healthy range. It has decreased from 26.73 (Mar 24) to 25.98, marking a decrease of 0.75.
• For PBIT Margin (%), as of Mar 25, the value is 23.07. This value exceeds the healthy maximum of 20. It has decreased from 23.89 (Mar 24) to 23.07, marking a decrease of 0.82.
• For PBT Margin (%), as of Mar 25, the value is 23.01. This value is within the healthy range. It has decreased from 23.77 (Mar 24) to 23.01, marking a decrease of 0.76.
• For Net Profit Margin (%), as of Mar 25, the value is 17.07. This value exceeds the healthy maximum of 10. It has decreased from 17.83 (Mar 24) to 17.07, marking a decrease of 0.76.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 15.85. This value is within the healthy range. It has decreased from 16.55 (Mar 24) to 15.85, marking a decrease of 0.70.
• For Return on Networth / Equity (%), as of Mar 25, the value is 15.63. This value is within the healthy range. It has decreased from 28.80 (Mar 24) to 15.63, marking a decrease of 13.17.
• For Return on Capital Employeed (%), as of Mar 25, the value is 20.26. This value is within the healthy range. It has decreased from 33.70 (Mar 24) to 20.26, marking a decrease of 13.44.
• For Return On Assets (%), as of Mar 25, the value is 12.82. This value is within the healthy range. It has decreased from 16.79 (Mar 24) to 12.82, marking a decrease of 3.97.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.31 (Mar 24) to 0.00, marking a decrease of 0.31.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.92. It has decreased from 1.14 (Mar 24) to 0.92, marking a decrease of 0.22.
• For Current Ratio (X), as of Mar 25, the value is 9.31. This value exceeds the healthy maximum of 3. It has increased from 2.39 (Mar 24) to 9.31, marking an increase of 6.92.
• For Quick Ratio (X), as of Mar 25, the value is 6.79. This value exceeds the healthy maximum of 2. It has increased from 1.56 (Mar 24) to 6.79, marking an increase of 5.23.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.33. This value is within the healthy range. It has decreased from 4.49 (Mar 24) to 4.33, marking a decrease of 0.16.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.77. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 24) to 9.77, marking an increase of 9.77.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.26. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 24) to 8.26, marking an increase of 8.26.
• For Earning Retention Ratio (%), as of Mar 25, the value is 90.23. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 90.23, marking an increase of 90.23.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.74. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 91.74, marking an increase of 91.74.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 382.19. This value is within the healthy range. It has increased from 209.44 (Mar 24) to 382.19, marking an increase of 172.75.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 252.25. This value is within the healthy range. It has increased from 140.68 (Mar 24) to 252.25, marking an increase of 111.57.
• For Enterprise Value (Cr.), as of Mar 25, the value is 12,217.61. It has decreased from 16,958.80 (Mar 24) to 12,217.61, marking a decrease of 4,741.19.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.72. This value exceeds the healthy maximum of 3. It has decreased from 8.48 (Mar 24) to 5.72, marking a decrease of 2.76.
• For EV / EBITDA (X), as of Mar 25, the value is 22.01. This value exceeds the healthy maximum of 15. It has decreased from 31.71 (Mar 24) to 22.01, marking a decrease of 9.70.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.65. This value exceeds the healthy maximum of 3. It has decreased from 8.22 (Mar 24) to 5.65, marking a decrease of 2.57.
• For Retention Ratios (%), as of Mar 25, the value is 90.22. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 90.22, marking an increase of 90.22.
• For Price / BV (X), as of Mar 25, the value is 5.57. This value exceeds the healthy maximum of 3. It has decreased from 14.31 (Mar 24) to 5.57, marking a decrease of 8.74.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.65. This value exceeds the healthy maximum of 3. It has decreased from 8.22 (Mar 24) to 5.65, marking a decrease of 2.57.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness